Effects of aminoguanidine and N(G)-nitro-L-arginine methyl ester on vascular responses of aortae and lungs from streptozotocin-diabetic rats

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 56, Issue 4, 1997, Pages 317-324

  Dewhurst, M ^a   Stevens, E J ^a   Tomlinson, D R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; AMINOGUANIDINE; ANGIOTENSIN; INDOMETACIN; N(G) NITROARGININE METHYL ESTER; PHENYLEPHRINE; PROSTACYCLIN;

ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; ENDOTHELIUM; IN VITRO STUDY; LUNG; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; VASODILATATION;

ANIMALIA;

EID: 0030941725     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-3278(97)90576-7     Document Type: Article

References (38)

1. Soulis-Liparota T., Cooper M., Papazoglou D., Clarke B., Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991; 40: 1328-1334.
2. Yagihashi S., Kamijo M., Baba M., Yagihashi N., Nagai K. Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes 1992; 41: 47-52.
3. Kihara M., Schmelzer J. D., Poduslo J. F., Curran G. L., Nickander K. K., Low P. A. Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc Natl Acad Sci USA 1991; 88: 6107-6111.
4. Hammes H.-P., Martin S., Federlin K., Geisen K., Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 1991; 88: 11555-11558.
5. Brownlee M., Vlassara H., Kooney A., Ulrich P., Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232: 1629-1632.
6. Brownlee M. Lilly Lecture 1993. Glycation and diabetic complications. [Review]. Diabetes 1994; 43: 836-841.
7. Huijberts M. S., Wolffenbuttel B. H., Boudier H. A. et al. Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. J Clin Invest 1993; 92: 1407-1411.
8. Hill M. A., Larkins R. G. Altered microvascular reactivity in streptozotocin-induced diabetes in rats. Am J Physiol 1989; 257:H1438-H1445.
9. Huijberts M. S. P., Wolffenbuttel B. H. R., Crijns F. R. L., Nieuwenhuijzen Kruseman A. C., Bemelmans M. H. A., Struijker Boudier H. A. J. Aminoguanidine reduces regional albumin clearance but not urinary albumin excretion in streptozotocindiabetic rats. Diabetologia 1994; 37: 10-14.
10. Tilton R. G., Chang K., Hasan K. S. et al. Prevention of diabetic vascular dysfunction by guanidines: Inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 1993; 42: 221-232.
11. Gross S. S., Wolin M. S. Nitric oxide: Pathophysiological mechanisms. Annu Rev Physiol 1995; 57: 737-769.
12. Cotter M. A., Dines K. C., Cameron N. E. Prevention and reversal of motor and sensory peripheral nerve conduction abnormalities in streptozotocin-diabetic rats by the prostacyclin analogue iloprost. Naunyn Schmiedebergs Arch Fharmacol 1993; 347: 534-540.
13. Furchgott R. F., Zawadski J. V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 286: 373-376.
14. Poston L., Taylor P. D. Endothelium-mediated vascular function in insulin-dependent diabetes mellitus. Clin Sci 1995; 88: 245-255.
15. Stevens E. J., Willars G. B., Lidbury P., House F., Tomlinson D. R. Vasoreactivity and prostacyclin release in streptozotocin-diabetic rats: effects of insulin or aldose reductase inhibition. Br J Pharmacol 1993; 109: 980-986.
16. Stevens E. J., Carrington A. L., Tomlinson D. R. Prostacyclin release in experimental diabetes: effects of evening primrose oil. Prostaglandins Leukot Essent Fatty Acids 1993; 49: 699-706.
17. Oyama Y., Kawasaki H., Hattori Y., Kanno M. Attenuation of endothelium-dependent relaxation in aorta from diabetic rats. Eur J Pharmacol 1986; 132: 75-78.
18. Palmer R. M., Ferrige A. G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-526.
19. Jeremy J. Y., Thompson C. S., Mikhailidis D. P., Owen R. H., Dandona P. Fasting and diabetes mellitus elicit opposite effects on agonist-stimulated prostacyclin synthesis by the rat aorta. Metabolism 1987; 36: 616-620.
20. Harrison H. E., Reece A. H., Johnson M. Decreased vascular prostacyclin in experimental diabetes. Life Sci 1978; 23: 351-356.
21. Griffiths M. J., Messent M., MacAllister R. J., Evans T. W. Aminoguanidine selectively inhibits inducible nitric oxide synthase. Br J Pharmacol 1993; 110: 963-968.
22. Wolff D. J., Lubeskie A. Aminoguanidine is an isoform-selective, mechanism-based inactivator of nitric oxide synthase. Arch Biochem Biophys 1995; 316: 290-301.
23. Bieganski T., Osinska Z., Maslinski C. Inhibition of plant and mammalian diamine oxidases by hydrazine and guanidine compounds. International J Biochem 1982; 14: 949-953.
24. Kusche J., Mennigen R., Leisten L, Amoei B. Elevation of the large bowel histamine concentration by aminoguanidine induced diamine oxidase inhibition. Agents Actions 1987; 20: 274-276.
25. Schoeffter P., Godfraind T. Characterization of histamine-induced contraction in rat isolated aorta. Eur J Pharmacol 1991; 197: 193-200.
26. Russell P. C., Wright C. E., Barer G. R., Howard P. Histamine induced pulmonary vasodilatation in the rat: site of action and changes in chronic hypoxia. Eur Respir J 1994; 7: 1138-1144.
27. Gill D. S., Thompson C. S., Dandona P. Histamine synthesis and catabolism in various tissues in diabetic rats. Metabolism 1990; 39: 815-818.
28. Jeremy J. Y., Thompson C. S., Mikhailidis D. P. Differential changes of adrenoceptor- and muscarinic receptor-linked prostacyclin synthesis by the aorta and urinary bladder of the diabetic rat. Br J Pharmacol 1993; 108: 1131-1136.
29. Doni M. G., Whittle B. J., Palmer R. M., Moncada S. Actions of nitric oxide on the release of prostacyclin from bovine endothelial cells in culture. Eur J Pharmacol 1988; 151: 19-25.
30. Pieper G. M., Peltier B. A. Amelioration by L-arginine of a dysfunctional arginine/nitric oxide pathway in diabetic endothelium. J Cardiovasc Pharmacol 1995; 25: 397-403.
31. Rees D. D., Palmer R. M., Schulz R., Hodson H. F., Moncada S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 1990; 101: 746-752.
32. Macarthur H., Hecker M., Busse R., Vane J. R. Selective inhibition of agonist-induced but not shear stress-dependent release of endothelial autacoids by thapsigargin. Br J Pharmacol 1993; 108: 100-105.
33. Berthiaume F., Frangos J. A. Flow-induced prostacyclin production is mediated by a pertussis toxin-sensitive G protein. FEBS Lett 1992; 308: 277-279.
34. Voelkel N. F., Gerber J. G., McMurtry I. F., Nies A. S., Reeves J. T. Release of vasodilator prostaglandin, PGI2, from isolated rat lung during vasoconstriction. Circ Res 1981; 48: 207-213.
35. Voelkel N. F., Gerber J. G., McMurtry I. F., Reeves J. T., Nies A. S. Release of dilator prostaglandins from rat lung during angiotensin II-induced vasoconstriction. Adv Prost Throm Res 1980; 7: 957-960.
36. Ercan Z. S., Zengil H., Akar F., Turker R. K. Possible prostacyclinmediated vascular effect of angiotensin II in the isolated perfused rat lung. Prostaglandins Leukot Med 1983; 12: 77-83.
37. Valentovic M. A., Lubaway W. C. Impact of insulin or tolbutamide treatment on 14C-arachidonic acid conversion to prostacyclin and/or thromboxane in lungs, aortas, and platelets of streptozotocin-induced diabetic rats. Diabetes 1983; 32: 846-851.
38. Shindo H., Tawata M., Aida K., Onaya T. Clinical efficacy of a stable prostacyclin analog, iloprost, in diabetic neuropathy. Prostaglandins 1991, 41: 85-96.